Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 8, 2018

Illumina and KingMed to develop oncology diagnostics in China

US-based gene sequencing firm Illumina has signed an agreement with Guangzhou KingMed Diagnostics Group to co-develop new oncology and hereditary disease testing applications in China.

US-based gene sequencing firm Illumina has signed an agreement with Guangzhou KingMed Diagnostics Group to co-develop new oncology and hereditary disease testing applications in China.

Under the collaboration, Illumina’s next-generation sequencing (NGS) technology will be used to create an integrated NGS system to provide cost-effective and ready-to-use in-vitro diagnostic (IVD) assays for testing molecular oncology and hereditary cancer.

The system will integrate Illumina’s MiniSeq System and associated sequencing consumables with KingMed’s testing components such as library preparation kits and software for analysis.

Illumina Greater China vice-president and general manager Ruilin Zhao said: “This agreement is a clear demonstration of our commitment to working with broader clinical testing service providers in China who want to develop and commercialise IVDs based on NGS.

“As we continue to expand our clinical partner networks, we are focused on providing the best healthcare solutions to patients throughout China.”

“As we continue to expand our clinical partner networks, we are focused on providing the best healthcare solutions to patients throughout China.”

Intended to deliver precision medicine to patients, the system will be available through KingMed’s clinical network, after review and approval by the China Food and Drug Administration (CFDA).

Content from our partners
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials
Precision wire: The future of bespoke medical treatment

KingMed Diagnostics chairman and CEO Yaoming Liang said: “Our mission is to bring state-of-the-art technology to Chinese patients by enhancing their standard of care and improving their outcomes.

“Illumina is the ideal collaborator because they have a proven track record of working with multiple domestic companies in China, in addition to being the first company with a US FDA-cleared, next-generation sequencing instrument.”

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU